2c-b

2C-B (4-Bromo-2,5-dimethoxyphenethylamine) is a hallucinogenic medication initially combined in 1974 by Dr. Alexander Shulgin.

2C-B is viewed as both a psychedelic drug and a gentle entactogenic.

“Entactogen” signifies “contacting inside,” and is a term utilized by therapists to characterize MDMA and related drugs

what is 2c b?

2CB (2-(4-chlorophenyl) -1-(1,1-dimethylethyl)-1H-benzimidazole) is a cannabinoid agonist at both CB1 and CB2 receptors.

It was first synthesized in 1992 and patented in 1993.

In addition to its use as a research tool, 2CB is being investigated for potential therapeutic uses.

In 2009, the United States Food and Drug Administration approved GW Pharmaceutical’s Sativex spray for treatment of spasticity due to Multiple sclerosis.

2CB has been shown to have antiemetic effects and may also be effective for treating migraine headaches.

2CB has also been studied extensively in the field of neuroscience; however, it has not yet been fully explored.